Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.

By P. McGettigan, D. Henry. Journal of the American Medical Association (JAMA), 2006

1,125 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Guidelines for Prevention of NSAID-Related Ulcer Complications (2009, background): “Both diclofenac and indomethacin were associated with an increased CV risk similar to that of rofecoxib (”
2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2008, background): “The risk appears to be amplified in patients with established cardiovascular disease (15, 18 ,19).”
Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis (2011, background): “Since then debate has surrounded the cardiovascular safety of cyclo-oxygenase-2 selective inhibitors, followed by similar concerns about traditional non-steroidal anti-inflammatory drugs.”